

obesity

Association of the rs4988235 in the lactase gene with obesity and its modulation by dairy products in a Mediterranean population

Journal:	<i>Obesity</i>
Manuscript ID:	10-0827-Orig
Manuscript Type:	Original Article
Date Submitted by the Author:	27-Aug-2010
Complete List of Authors:	Corella, Dolores; School of Medicine, Preventive Medicine Department Arregui, Maria; University of Valencia, Preventive Medicine Coltell, Oscar; University Jaume I, Computer Sciences Portoles, Olga; University of Valencia, Preventive Medicine Guillem-Saiz, Patricia; University of Valencia, Preventive Medicine Carrasco, Paula; University of Valencia, Preventive Medicine Sorli, Jose; University of Valencia, Preventive Medicine Ortega-Azorin, Carolina; University of Valencia, Preventive Medicine Gonzalez, Jose; University of Valencia, Preventive Medicine Ordovas, Jose; USDA-HNRCA at Tufts Univ, Nutrition and Genomics
Keywords:	Abdominal obesity, Diet, Genotype, Metabolic Syndrome, Obesity Phenotypes

SCHOLARONE™
Manuscripts

1
2
3 **Association of the rs4988235 in the lactase gene with obesity and its modulation by dairy**
4 **products in a Mediterranean population**
5
6
7

8
9
10 Corella D^{1,2,3*}, Arregui M^{1,2,4*}, Coltell O^{3,4}, Portolés O^{1,2}, Guillem-Sáiz P^{1,2}, Carrasco P^{1,2}, Sorlí
11 JV^{1,2,5}, Ortega-Azorín C^{1,2}, González JI^{1,2}, Ordovás JM^{2,3,6}
12
13
14

- 15
16
17 1. Genetic and Molecular Epidemiology Unit School of Medicine. University of Valencia,
18 Valencia, Spain.
19
20 2. CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, Spain.
21
22 3. Nutrition and Genomics Laboratory, JM-USDA Human Nutrition Research Center on Aging at
23 Tufts University, Boston, MA.
24
25 4. Department of Computing Languages and Systems. University Jaume I, Castellón, Spain.
26
27 5. Primary Care Health Center. Generalitat Valenciana. Xirivella, Valencia, Spain
28
29 6. Department of Cardiovascular Epidemiology and Population Genetics, Centro Nacional de
30 Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
31
32
33
34
35

36
37 *: These authors contributed equally to this work.
38
39
40

41 **For Correspondence:**

42 Dolores Corella, PhD

43 Genetic and Molecular Epidemiology Unit. University of Valencia.

44 Blasco Ibañez, 15

45 46010-Valencia, Spain

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Tel: (+34) 963864417; Fax: (+34) 963864166; E-mail: dolores.corella@uv.es

ABSTRACT

The -13910C>T polymorphism (rs4988235) upstream from the lactase (*LCT*) gene, strongly associated with lactase persistence (LP) in Europeans, is emerging as a new candidate for obesity. Our aim was to analyze the association of rs4988235 with obesity-related variables and its modulation by dairy product intake in an elderly population. We studied 940 White subjects (aged 67+/-7 years) from the Spanish Mediterranean population. Dairy product consumption was assessed by a validated questionnaire. Anthropometric variables were directly measured, and metabolic-syndrome (MetS)-related variables were obtained. Prevalence of the CC genotype (38.0%) [lactase non-persistent (LNP)] was higher than in northern Europe. CT and TT were 45.7% and 16.3%, respectively. The CC genotype was not associated with lower milk or dairy product consumption in the whole population. Only in women was dairy intake significantly lower in CC subjects. The most important association was obtained with anthropometric measurements. CC individuals had lower weight (P=0.032), lower BMI (29.7+/-4.2 vs 30.6+/-4.2 Kg/m²;P=0.003) and lower waist circumference (101.1+/-11.8 vs 103.5+/-11.5 cm;P=0.005) than T-allele carriers. Obesity risk was also significantly higher in T-allele carriers than in CC individuals (OR:1.38; 95% CI:1.05-1.81; P=0.01), and remained significant after adjustment for sex, age, diabetes, physical activity and energy intake. Dairy lactose intake modulated these associations, being higher with higher lactose intake. No significant associations with lipids, glucose or blood pressure were obtained after adjustment for BMI. In conclusion, despite not finding marked differences in dairy product consumption, the rs4988235 polymorphism was strongly associated with obesity and modulated by lactose intake in this Mediterranean population.

Key words: Lactase, obesity, gene, dairy products, lactose, metabolic syndrome, Mediterranean

INTRODUCTION

The association of dairy food consumption with obesity and other cardiovascular risk factors has been investigated in several studies, but with contradictory results (1-6). A beneficial effect of dairy consumption on the incidence of various metabolic syndrome components (including obesity, glucose intolerance, hypertension, and dyslipidemia) was reported by Pereira et al (1) in the CARDIA study and replicated in some (2-4), but not all (5,6) subsequent studies. Some meta-analyses carried out for this purpose reflect the inconsistency of results and underline the need to analyse the different factors involved in greater depth (7-9). One of the potential factors that may affect the quantity of milk consumed as well as the effects of dairy products on obesity and obesity-related variables in adults is lactose intolerance or lactase non-persistence (LNP). Lactose intolerance is the syndrome of diarrhoea, abdominal pain or flatulence, occurring after lactose ingestion (10). These symptoms, caused by a decreased ability to hydrolyze lactose due to a deficiency in the enzyme lactase, may have an influence in the amount of dairy product consumed. On the other hand, if there is no restriction of dairy products in LNP subjects, the undigested lactose may have several metabolic effects that may be related to obesity.

Lactase is coded by the lactase gene (*LCT*), and *LCT* activity remains high until weaning, then it fades away in most of the adult population (adult-type hypolactasia or LNP). A single nucleotide polymorphism (SNP) (rs4988235), located at -13910 bp upstream from the *LCT* gene (-13910C > T) within intron 13 of the adjacent minichromosome maintenance 6 (*MCM6*) gene was found to be associated with LNP (11). Various studies (11-13) have demonstrated that the -13910C > T SNP is functional and is associated with changes in *LCT* gene expression. Individuals homozygous for the C allele (LNP) have almost undetectable levels of intestinal lactase production compared to TC or TT individuals [lactase persistent (LP), following a codominant model] (11). Pohl et al (14) found an excellent agreement between the lactose hydrogen test (10) and the

1
2
3 genetic test based on this SNP for LNP in Europeans. The frequency of LP is high in northern
4
5 European populations, decreases across southern Europe and more than half of the world's
6
7 population is LNP (15). Although some studies have associated the CC genotype with a lower
8
9 consumption of milk (16-18), this association is not always observed (19-21).
10
11

12 Interestingly, the *LCT* gene is emerging as a new candidate gene related with obesity and
13
14 other anthropometric measurements. Hence, in a recent Genome-Wide Association Study (GWAs)
15
16 carried out by CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology), the
17
18 Consortium (22) found a strong association between various SNPs in the *LCT* gene and waist
19
20 circumference. Likewise, Kettunen et al (23), undertook a meta-analysis on eight European
21
22 cohorts (in which the Mediterranean population was not included) finding a strong association
23
24 between the LP variant (T allele, rs4988235) and higher body mass index (BMI). However, none
25
26 of the published studies has analyzed the joint influence of the LP genotype and dairy product
27
28 consumption on obesity. Therefore, our aim was to study the association of the -13910C>T SNP
29
30 with obesity and obesity-related variables as well as its modulation by lactose intake in an elderly
31
32 Mediterranean population.
33
34
35
36
37
38
39

40 **MATERIAL AND METHODS**

41 **Subjects and study design**

42
43
44 We studied 940 unrelated White individuals (338 men and 602 women), mean age 67.3+/-
45
46 6.5 years, who participated in the PREDIMED (Prevención con Dieta MEDiterránea) study, were
47
48 consecutively recruited in the Valencia Region (on the East Mediterranean coast of Spain) from
49
50 October 2003 to December 2008 and had the -13910C>T SNP genotype determined. All
51
52 participants gave their informed consent. The ethics committee of the University of Valencia
53
54 approved the study. Details of this study have been previously reported (24). Briefly, high
55
56
57
58
59
60

1
2
3 cardiovascular risk subjects were selected by physicians in Primary Care Centers participating in
4
5 the study. Eligible subjects were community-dwelling people (55-80 years of age for men; 60-80
6
7 years of age for women) who fulfilled at least one of two criteria: type 2 diabetes; 3 or more
8
9 cardiovascular risk factors (current smoking, hypertension, dyslipidemia, overweight, or a family
10
11 history of premature cardiovascular disease).
12
13

14 15 **Demographic, anthropometric and clinical measurements** 16

17
18 The baseline examination included assessment of standard socio-demographic factors,
19
20 clinical, biochemical and lifestyle variables, as previously detailed (24). Anthropometric variables
21
22 were directly measured by trained nurses by standard techniques at baseline (24). Height and
23
24 weight were measured with light clothing and no shoes. Obesity was defined as $BMI \geq 30 \text{ kg/m}^2$.
25
26 Waist circumference was measured midway between the lowest rib and the iliac crest using an
27
28 anthropometric tape. Trained personnel measured blood pressure with a validated semi-automatic
29
30 sphygmomanometer (Omron HEM-705CP, The Netherlands) in a seated position after a 5-min
31
32 rest. Physical activity was estimated by the Minnesota Leisure Time Physical Activity as
33
34 previously reported (24). Blood samples were obtained for each participant after an overnight fast
35
36 and were frozen at -80°C . Fasting glucose, total cholesterol, triglycerides, HDL-C and LDL-C
37
38 were determined as previously reported (24). The metabolic syndrome was defined according to
39
40 updated ATP III criteria (25), which require that 3 or more of the following conditions be met:
41
42 abdominal obesity (waist circumference >102 cm in men and >88 cm in women),
43
44 hypertriglyceridemia (triglycerides level 150 mg/dL), low HDL cholesterol level (<40 mg/dL in
45
46 men and <50 mg/dL in women), elevated fasting blood glucose level (100 mg/dL), and elevated
47
48 blood pressure (systolic 130 mm Hg, diastolic 85 mm Hg, or taking antihypertensive medication).
49
50 Participants who were being treated with antidiabetic, antihypertensive, or triglyceride-lowering
51
52
53
54
55
56
57
58
59
60

1
2
3 medications were considered to be diabetic, hypertensive, or hypertriglyceridemic, respectively.
4
5

6 **Dietary measurements**

7

8 Food consumption was determined by a validated (26) semi-quantitative 137-item food
9 frequency questionnaire (FFQ). Energy and nutrient intake were calculated from Spanish food
10 composition tables (27). Lactose content was not available in the Spanish tables and so foreign
11 food composition tables were used (Fineli Food Composition Database, Finland, release 2010).
12
13 The questionnaire was based on the typical portion sizes that were multiplied by the consumption
14 frequency for each food. Information about dairy products was assessed in fifteen items of the
15 semi-quantitative FFQ (whole-fat milk, partially skimmed milk, skimmed milk, condensed milk,
16 whipped cream, yoghurt, skimmed yoghurt, milkshake, ricotta cheese or junket, petit Suisse
17 cheese, spreadable cheese wedges, cottage cheese, other cheese, custard, and ice cream). We
18 calculated total dairy products intake (in g/d) for each individual on the basis of the type and
19 amount consumed.
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **DNA extraction and genotyping**

35

36 Genomic DNA was isolated from blood. The rs4988235 *LCT* SNP was determined using a
37 7900HT Sequence Detection system (Applied Biosystems) and a customized fluorescent allelic
38 discrimination TaqMan assay by standard procedures. For quality control purposes, 50% of
39 randomly selected samples were also genotyped by restriction fragment length polymorphism
40 analysis. Concordance between techniques was higher than 95%. Discrepant samples were
41 sequenced. Information on probes and polymerase chain reaction conditions for genotyped single
42 nucleotide polymorphisms can be obtained from the authors upon request.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical analysis

χ^2 tests were used to test differences in percentages. Taking into account that the genetically defined LP is considered to follow a dominant model, CT and TT subjects (LP) were grouped and compared with CC subjects for the statistical analysis after having checked that this dominant model is observed in this Mediterranean population. We applied the t tests to compare crude means for normally distributed variables. Alcohol and dairy product consumption did not follow a normal distribution and we applied the non-parametric Mann-Whitney U test. For continuous anthropometric variables, multivariate adjustment was carried out by linear regression analysis. Model were adjusted for sex, age (as continuous), diabetes, total energy intake (as continuous) and physical activity (as continuous). Additional adjustment for dairy product consumption was also done. Multivariate adjustment of plasma lipids, fasting glucose and blood pressure was also carried out by linear regression. Regression coefficients and adjusted means for each predictor were estimated from the multivariate models. Regression models with interaction terms and as well as stratified analysis were applied to test the homogeneity of effects by gender and lactose intake. Logistic regression models were fitted to estimate the odds ratio (OR) and 95% confidence interval (CI) of obesity and obesity-related variables associated with the LP genotype compared with LNP. Analyses were performed using the SPSS statistical software, version 17.0 (SPSS Inc, Chicago, Illinois).

RESULTS

Table 1 shows general characteristics of the study subjects by gender. Prevalence of obesity, diabetes and metabolic syndrome was high given that this study involved a population that was selected for being elderly and with a high cardiovascular risk. Total dairy product

1
2
3 consumption was higher in women than in men (395.2 \pm 229.6 g/d vs 322.3 \pm 193.9 g/d,
4
5 respectively; $P < 0.001$). Men consumed a greater amount of whole-fat milk whereas women
6
7 consumed more skimmed milk and skimmed yoghurt, and there were no significant differences
8
9 between men and women in the amount of whole-fat yoghurt consumed. Likewise, total cheese
10
11 intake did not differ between men and women. The amount of lactose intake derived from dairy
12
13 products was also significantly higher in women than men ($P = 0.01$). However, there were no
14
15 significant differences in the percentage of men and women who claim never to consume milk
16
17 (14.2% vs 14%; $P = 0.994$).
18
19
20
21

22
23 Prevalence of the *LCT* -13910 C>T genotypes were: CC (LNP) 38.0% (n=357), CT 45.7%
24
25 (n=430) and TT 16.3% (n=153). Carriers of the T allele were the genetically determined LP
26
27 subjects. This distribution was in Hardy-Weinberg equilibrium ($P = 0.221$) and did not differ
28
29 between men and women ($P = 0.577$).
30
31

32 **Association between the rs4988235 SNP and dairy product intake**

33
34
35 **Table 2** shows mean intake of milk and dairy products (total and by gender) depending on
36
37 the *LCT* -13910 C>T genotypes. The results are shown grouping the T carriers together (LP) and
38
39 comparing them with CC subjects (LNP). Total energy intake did not differ between CC and
40
41 subjects carrying the T- allele. Likewise, we did not find significant differences in physical activity
42
43 depending on the *LCT* genotype (not shown). On analysing the results for men and women jointly,
44
45 it is observed that although dairy product consumption tended to be lower in CC subjects, the
46
47 differences did not reach statistical significance. Neither was the total consumption of milk or the
48
49 contribution of lactose or calcium through dairy products lower. Statistically significant
50
51 differences were only reached in the consumption of skimmed yoghurt, which was lower in CC
52
53
54
55
56
57
58
59
60 subjects.

1
2
3 On analysing the results per gender, it can be observed that in men the differences in milk
4 and dairy product intake depending on genotype were minimal and did not reach statistical
5 significance for any comparison. In women, these differences were more accentuated; reaching
6 statistical significance in the consumption of skimmed yoghurt (lower in CC subjects) and when
7 the consumption of skimmed yoghurt, skimmed milk and partially skimmed milk were analyzed
8 together (265.1 +/- 207.9 g/d vs 317.6 +/- 239.2 g/d in CC vs CT+TT; P=0.014). Likewise, the total
9 consumption of dairy products also reached statistically significant differences in women
10 depending on the *LCT* genotype (P=0.045). No significant differences of lactose intake were
11 found.
12
13
14
15
16
17
18
19
20
21
22
23

24 **Association between the rs4988235 SNP with anthropometric variables**

25
26
27 We observed that the *LCT* -13910 C>T SNP presented a strong association with
28 anthropometric measures (**Table 3**). CC individuals, although they do not differ in height from the
29 other genotypes, had significantly less weight, a lower BMI and less waist-circumference than T-
30 allele carriers. These differences remained statistically significant when the models were adjusted
31 for gender and age, and even after additional adjustment for diabetes, physical activity and total
32 energy intake. These associations were homogeneous by gender, and both in men and women CC
33 subjects have lower means of anthropometric measurements than T-allele carriers (P for
34 interaction *LCT* genotype x gender were 0.738, 0.872 and 0.942 for weight, BMI and waist
35 circumference, respectively).
36
37
38
39
40
41
42
43
44
45
46
47
48

49
50 Next, we analyzed the association of the *LCT* -13910 C>T SNP with obesity (Table 3).
51 Considering CC individuals as the reference category, we observed that T-allele carriers have a
52 greater risk (OR) of obesity, both unadjusted (OR: 1.39; 95% CI: 1.07-1.82; P=0.014) and after
53 adjustment for gender, age, diabetes, physical activity and total energy intake (OR: 1.37; 95% CI:
54
55
56
57
58
59
60

1
2
3 1.03-1.81; $P=0.029$). Homogeneity by gender was also observed between men and women in this
4
5 association (P for interaction $LCT \times \text{gender} = 0.826$). Subsequent adjustments for dairy product
6
7 intake do not modify the statistical significance of the associations of the $LCT -13910 C>T$ SNP
8
9 with the anthropometric variables (not shown).
10
11

12 **Modulation of the association between the rs4988235 SNP with anthropometric variables by** 13 **lactose intake** 14 15

16
17
18 Considering that CC subjects may tolerate low amounts of lactose intake without
19
20 gastrointestinal symptoms, we hypothesized that dairy lactose intake may modulate the effects of
21
22 the $LCT -13910 C>T$ SNP on anthropometric variables. We first tested the interaction effect
23
24 between the $LCT -13910 C>T$ SNP and dairy lactose intake as continuous. Taking into account
25
26 dairy lactose intake was not normally distributed, eight identified outliers (corresponding to 8
27
28 TC+TT subjects with lactose intake higher than 50g/d) were removed to improve normality for this
29
30 linear regression analysis. We found a statistically significant interaction term between lactose
31
32 intake and the $LCT -13910 C>T$ SNP in determining waist circumference ($P=0.044$ after
33
34 adjustment for sex, age, diabetes, total energy intake and physical activity). According to this
35
36 interaction, a higher dairy lactose intake increased the differences in waist-circumference between
37
38 CC and CT+TT individuals (**Figure 1 A**). We also tested this modulation by lactose intake as a
39
40 categorical variable. Three categories of lactose intake based on habitual milk consumption
41
42 equivalence were considered (**Figure 1B**). No differences in the $LCT -13910 C>T$ genotype
43
44 distribution among categories (low, intermediate and high) of lactose intake ($P=0.518$) were
45
46 observed. When lactose intake was low [less than one small cup per day (≤ 8 g lactose/d); 20% of
47
48 the population], we did not find significant differences in waist-circumference between CC and T-
49
50 allele carriers ($P=0.808$). When lactose intake was intermediate [between 1 and 2 small or large
51
52
53
54
55
56
57
58
59
60

1
2
3 cups of milk per day (8-24 g lactose/d); 50% of the population], significant differences in waist
4
5 circumference between *LCT* genotypes were detected (P=0.012). These differences increased in
6
7 magnitude when higher intakes of lactose were observed [more than 2 large cups of milk per day
8
9 (>24 g lactose/d); 30% of the population].

10
11
12
13 In terms of obesity risk, in subjects with a low lactose intake (≤ 8 g/d) we did not find
14
15 significant association between the *LCT* -13910 C>T SNP and obesity in the crude model
16
17 (OR=1.03, 95%CI: 0.55-1.91; P=0.910) or in the model adjusted for sex, age, diabetes, physical
18
19 activity and total energy intake (OR=1.05, 95%CI: 0.54-2.01; P=0.891). However, when lactose
20
21 intake was higher (>8 g/d), we did observe a significant association of the CT+TT genotype with
22
23 higher obesity risk (OR: 1.50, 95%CI: 1.10-2.03; P=0.012 in the crude model and OR: 1.44,
24
25 95%CI: 1.05-1.96; P=0.022 in the model adjusted for sex, age, diabetes, physical activity and total
26
27 energy intake).

31 32 **Association between the rs4988235 SNP with the metabolic syndrome related variables**

33
34
35 Finally, we studied the association of the *LCT* SNP with biochemical parameters (fasting
36
37 glucose, and plasma lipids), and blood pressure (**Table 4**) and observed that, after adjustment for
38
39 BMI, there were no statistically significant differences in total cholesterol, LDL-C, HDL-C, TG,
40
41 fasting glucose concentrations or blood pressure between CC subjects and T-allele carriers. When
42
43 we analyzed the association of the *LCT* SNP with the Metabolic syndrome, taking CC individuals
44
45 as the reference category, although the magnitude of the OR in T-allele carriers was greater than 1,
46
47 it did not reach statistical significance, either adjusted for gender and age (OR: 1.26; 95%CI: 0.95-
48
49 1.68; P=0.114) or after additional adjustment for physical activity and total energy intake (OR:
50
51 1.24; 95%CI: 0.92-1.67; P=0.164). When we tested the potential modulation by lactose intake, we
52
53 found that in subjects with a low lactose intake (≤ 8 g/d), the *LCT* SNP was not associated with
54
55
56
57
58
59
60

1
2
3 the metabolic syndrome (OR adjusted for sex, age, physical activity and energy intake: 0.98,
4
5 95%CI: 0.49-1.96; P=0.955), this association being statistically significant in subjects with lactose
6
7 intake higher than 8 g/d (OR adjusted for sex, age, physical activity and energy intake: 1.40,
8
9 95%CI: 1.02-1.90; P=0.040). However, this association was mainly mediated by abdominal
10
11 obesity. It was the only component of the metabolic syndrome that was significantly associated
12
13 with the *LCT* polymorphism.
14
15
16
17
18
19

20 21 **DISCUSSION**

22
23
24 In this study carried out on a high cardiovascular risk Mediterranean population, we have
25
26 detected a high prevalence of CC individuals (LNP) in contrast to that found in northern European
27
28 populations, where the opposite situation is found (15,28). Although the effect of the *LCT*
29
30 polymorphism on the differences of milk and dairy product consumption was not very high in the
31
32 population as a whole, the association that we have found with anthropometric measurements is
33
34 particularly relevant. In this Mediterranean population, CC individuals had significantly lower
35
36 BMI, lesser waist circumference and lower risk of obesity than T-allele carriers even after
37
38 adjustment for sex, age, diabetes, physical activity and total energy intake. Moreover, we reported
39
40 for the first time that the association between the -13910C > T *LCT* SNP and anthropometric
41
42 variables is modulated by dairy lactose intake. These observations are in line with the results
43
44 obtained in a recently published meta-analysis (23) that reported novel evidence of association
45
46 between the -13910C>T *LCT* polymorphism and BMI ($P = 7.9 \times 10^{-5}$) in 31,720 European
47
48 individuals. Eight cohorts were included, five of which were of Finnish origin (with a high milk
49
50 intake), and the others from Holland and England, without including a Mediterranean population.
51
52 They observed that the CC genotype was associated with decreased BMI compared to CT/TT
53
54
55
56
57
58
59
60

1
2
3 genotypes in the meta-analysis, and that this effect was observed in the same direction for both
4
5 men and women. They also observed that this effect was due to the influence of the genotype on
6
7 weight and not on height. Moreover, they discarded population stratification as being responsible
8
9 for these effects. In our study, the probability of the influence of population stratification is very
10
11 low, as we carried it out on White subjects recruited in a single region of Spain with a
12
13 homogenous ethnic background. Another study undertaken on a sample of 944 postmenopausal
14
15 Spanish women recruited in another Spanish region (Catalonia) aimed to investigate the
16
17 association of the *LCT* SNP with osteoporosis phenotypes obtained a similar frequency of -
18
19 13910C>T *LCT* genotypes (29). These researchers also found a significant association of the *LCT*
20
21 SNP with weight. Hence, TT women were 1.91 kg heavier than CT+CC women, adding
22
23 consistency to the association found in our study. However, in that same study, the authors did not
24
25 analyse the possible differences in waist circumference or obesity risk associated with the *LCT*
26
27 SNP, our study being the first to report such associations in a Mediterranean population.
28
29
30
31
32
33

34 Furthermore, our results were also the first to replicate the observations of the CHARGE
35
36 Consortium, where strong associations were found between various SNPs in the *LCT* gene and
37
38 waist-circumference (22). In line with those observations, a study carried out by Almon et al on
39
40 551 individuals of the general population of the Canary Islands (30), found that the prevalence of
41
42 central obesity was higher in CT+TT (62%) individuals than in CC individuals (55.9%). However,
43
44 those differences did not reach statistical significance possibly due to a smaller sample size.
45
46 Nevertheless, what they did observe was a greater risk of metabolic syndrome in CT+TT
47
48 individuals than in CC individuals (OR: 1.56; 95%CI: 1.06–2.31). In our study, carried out on a
49
50 Mediterranean population, and despite the tendency of the association with metabolic syndrome
51
52 being similar to that observed in the Canary islands, our results did not reach statistical
53
54 significance in the whole population, given that we observed the effects of the *LCT* SNP mainly on
55
56
57
58
59
60

1
2
3 anthropometric measurements and not on lipid concentrations, glucose or blood pressure.
4

5 However, in subgroup analysis, we observed a significant association between the metabolic
6
7 syndrome and the *LCT* SNP in subjects with lactose intake higher than 8g/d. Considering that milk
8
9 consumption was higher in the Canary Islands than in our population, both results are in
10
11 agreement. On the other hand, the differences observed between these two studies may be due to
12
13 the different ages of the population and associated risk factors. Thus, although in the study carried
14
15 out in the Canary Islands (mean age 45+/-15 years) CC individuals were found to consume less
16
17 milk than CT+TT individuals (246 vs 300 g/d; $P<0.05$), our study found no significant differences
18
19 in the amount of total milk consumed depending on the *LCT* SNP. Possibly, on dealing with an
20
21 elderly population in which calcium requirements are greater to minimize osteoporosis, medical
22
23 advice recommending higher milk consumption may have a greater influence, that
24
25 recommendation offsetting the genetic influence.
26
27
28
29
30
31

32 Other studies that have analysed the influence of the *LCT* SNP on milk and dairy product
33
34 consumption have also found differing associations depending on the age and gender of the
35
36 population analysed (16-21,31,32). In general, it seems that the influence of the *LCT* genotype on
37
38 dairy consumption is higher in women than in men. So, for example, in the study carried out by
39
40 Laaksonen et al in Finland (17), it was observed that in females with the CC genotype, milk and
41
42 milk product consumption was lowest from the age of 6 years to adulthood with higher differences
43
44 than those observed in males. In our study, CC women presented a lower total consumption of
45
46 low-fat milk and yoghurt and than T-carriers, as well as a lower total dairy product consumption,
47
48 which was not observed in men. One possible explanation could be that females and males differ
49
50 in their sensitivity to gastrointestinal symptoms caused by maldigested lactose, being stronger in
51
52 women (33).
53
54
55
56
57
58
59
60

1
2
3 Another possible explanation could be that as men consume less milk than women, the
4 amount of lactose does not pose a problem even for the LNP, as it has been reported that
5 gastrointestinal symptoms of intolerance to lactose are not important until consuming amounts
6 greater than 12 g of lactose/d (approximately 250 ml of milk) (34). Other authors indicate that
7 lactose maldigesters may be able to tolerate foods containing 6 g lactose or less per serving, such
8 as hard cheeses and small servings (120 mL or less) of milk (35). In our study we did not find
9 differences in the prevalence of the LP or LNP genotypes among the three categories of lactose
10 intake considered [low (≤ 8 g/d, intermediate (8-24 g/d) and high (>24 g/d)]. The symptoms of
11 lactose intolerance result from bacterial fermentation of undigested lactose in the colon (10).
12 Therefore, the same amount of lactose ingested can lead to different gastrointestinal effects in LNP
13 and LP subjects and these effects be related to the observed obesity phenotypes. In addition to
14 differences in abdominal pain, bloating, or diarrhoea that may be related to less weight (10),
15 various studies have shown differences in the microbial composition of fecal samples of the LP
16 and LNP individuals (36,37) that may relate to obesity even in the absence of gastrointestinal
17 symptoms. For example, Szilagy et al (37), observed that lactose maldigesters had differences in
18 bifidobacteria and lactobacilli counts compared with lactose digesters. Bearing in mind that recent
19 studies have shown differences between the gut microbiota in obese and non-obese individuals
20 (38-40), changes in the gut microbiota in LNP compared with LP subjects may be involved in the
21 lower risk of obesity observed in CC individuals, due to differing lactose fermentation capacity
22 and the subsequent multiple effects. This hypothesis, as well as the identification of additional
23 mechanisms to explain the association of the -13910C>T *LCT* SNP with obesity-related variables,
24 requires further studies in order to substantiate it. Supporting this hypothesis is our observation of
25 a possible greater effect of the *LCT* SNP on anthropometric measurements when the amounts of
26 lactose consumed are greater. When dairy lactose intake was low (≤ 8 g/d), we did not find
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 significant differences in waist circumference or obesity risk between CC and T-allele carriers.
4
5 However, significant differences in were found with higher lactose intake. This is the first time
6
7 that a modulation by the amount of lactose intake of the effects of the -13910C>T *LCT* SNP on
8
9 obesity is reported and requires replication in other populations. Moreover, our results suggest that
10
11 some of the controversial results obtained in previous studies investigating the effect of dairy
12
13 product consumption on obesity-related variables, may be explained by the potential
14
15 heterogeneous effects of these products on LNP and LP individuals in those cohorts. Therefore,
16
17 genotyping of the -13910C>T *LCT* SNP in these studies would be of interest to clarify the results.
18
19
20
21
22
23
24

25 **ACKNOWLEDGEMENTS**

26
27
28 **Funding/Support:** This work was supported by grants from the Ministerio de Ciencia e
29
30 Innovación, Spain (CIBER CB06/03/0035, RD07/0067/0006, PI6-1326, PI07-0954, PI08-90002
31
32 and SAF-09-12304), the Generalitat Valenciana, Spain (GVACOMP2010-181, BEST2010-211,
33
34 BEST2010-032) and the National Heart, Lung, and Blood Institute grants HL-54776, National
35
36 Institute of Diabetes and Digestive and Kidney Diseases, Grant Number DK075030 and by
37
38 contracts 53-K06-5-10 and 58-1950-9-001 from the US Department of Agriculture Research.
39
40
41

42 **Disclosure**

43
44
45 The authors declared no conflict of interest.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Pereira MA, Jacobs DR Jr, Van Horn L, Slattery ML, Kartashov AI, Ludwig DS. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study. *JAMA*. 2002;287:2081-9.
2. Mirmiran P, Esmailzadeh A, Azizi F. Dairy consumption and body mass index: an inverse relationship. *Int J Obes (Lond)*. 2005;29:115-21.
3. Azadbakht L, Mirmiran P, Esmailzadeh A, Azizi F. Dairy consumption is inversely associated with the prevalence of the metabolic syndrome in Tehranian adults. *Am J Clin Nutr*. 2005;82:523-30.
4. Elwood PC, Pickering JE, Fehily AM. Milk and dairy consumption, diabetes and the metabolic syndrome: the Caerphilly prospective study. *J Epidemiol Community Health*. 2007;61:695-8.
5. Snijder MB, van Dam RM, Stehouwer CD, Hiddink GJ, Heine RJ, Dekker JM. A prospective study of dairy consumption in relation to changes in metabolic risk factors: the Hoorn Study. *Obesity (Silver Spring)*. 2008;16:706-9.
6. Wennersberg MH, Smedman A, Turpeinen AM, et al. Dairy products and metabolic effects in overweight men and women: results from a 6-mo intervention study. *Am J Clin Nutr*. 2009;90:960-8.
7. Lamarche B. Review of the effect of dairy products on non-lipid risk factors for cardiovascular disease. *J Am Coll Nutr*. 2008;27:741S-6S.
8. German JB, Gibson RA, Krauss RM, et al. A reappraisal of the impact of dairy foods and milk fat on cardiovascular disease risk. *Eur J Nutr*. 2009;48:191-203.
9. Warensjo E, Nolan D, Tapsell L. Dairy Food Consumption and Obesity-Related Chronic Disease. *Adv Food Nutr Res*. 2010;59C:1-41.

- 1
2
3 10. Suchy FJ, Brannon PM, Carpenter TO, et al. National Institutes of Health Consensus
4
5 Development Conference: lactose intolerance and health. *Ann Intern Med.* 2010;152:792-
6
7 6.
8
9
- 10 11. Enattah NS, Sahi T, Savilahti E, Terwilliger JD, Peltonen L, Järvelä I. Identification of a
11
12 variant associated with adult-type hypolactasia. *Nat Genet.* 2002;30:233-7.
13
14
- 15 12. Olds LC, Sibley E. Lactase persistence DNA variant enhances lactase promoter activity in
16
17 vitro: functional role as a cis regulatory element. *Hum Mol Genet.* 2003;12:2333-40.
18
19
- 20 13. Lewinsky RH, Jensen TG, Møller J, Stensballe A, Olsen J, Troelsen JT .T-13910 DNA
21
22 variant associated with lactase persistence interacts with Oct-1 and stimulates lactase
23
24 promoter activity in vitro. *Hum Mol Genet.* 2005;14:3945-53.
25
26
- 27 14. Pohl D, Savarino E, Hersberger M, et al. Excellent agreement between genetic and
28
29 hydrogen breath tests for lactase deficiency and the role of extended symptom assessment.
30
31 *Br J Nutr.* 2010; 19:1-8.
32
33
- 34 15. Swallow DM. Genetics of lactase persistence and lactose intolerance. *Annu Rev Genet.*
35
36 2003;37:197-219.
37
38
- 39 16. Lehtimäki T, Hemminki J, Rontu R, et al. The effects of adult-type hypolactasia on body
40
41 height growth and dietary calcium intake from childhood into young adulthood: a 21-year
42
43 follow-up study--the Cardiovascular Risk in Young Finns Study. *Pediatrics.* 2006
44
45 ;118:1553-9.
46
47
- 48 17. Laaksonen MM, Mikkilä V, Räsänen L, et al. Genetic lactase non-persistence,
49
50 consumption of milk products and intakes of milk nutrients in Finns from childhood to
51
52 young adulthood. *Br J Nutr.* 2009;102:8-17.
53
54
55
56
57
58
59
60

- 1
2
3 18. Tornaiainen S, Hedelin M, Autio V, et al. Lactase persistence, dietary intake of milk, and
4
5 the risk for prostate cancer in Sweden and Finland. *Cancer Epidemiol Biomarkers Prev.*
6
7 2007;16:956-61.
8
9
- 10 19. Gugatschka M, Hoeller A, Fahrleitner-Pammer A, et al. Calcium supply, bone mineral
11
12 density and genetically defined lactose maldigestion in a cohort of elderly men. *J*
13
14 *Endocrinol Invest.* 2007;30:46-51.
15
16
- 17 20. Gugatschka M, Dobnig H, Fahrleitner-Pammer A, et al. Molecularly-defined lactose
18
19 malabsorption, milk consumption and anthropometric differences in adult males. *QJM.*
20
21 2005;98:857-63.
22
23
- 24 21. Smith GD, Lawlor DA, Timpson NJ, et al. Lactase persistence-related genetic variant:
25
26 population substructure and health outcomes. *Eur J Hum Genet.* 2009;17:357-67.
27
28
- 29 22. Heard-Costa NL, Zillikens MC, Monda KL, et al. NRXN3 is a novel locus for waist
30
31 circumference: a genome-wide association study from the CHARGE Consortium. *PLoS*
32
33 *Genet.* 2009;5(6):e1000539.
34
35
- 36 23. Kettunen J, Silander K, Saarela O, et al. European lactase persistence genotype shows
37
38 evidence of association with increase in body mass index. *Hum Mol Genet.* 2010;19:1129-
39
40 36.
41
42
- 43 24. Estruch R, Martínez-González MA, Corella D, et al. Effects of a Mediterranean-style diet
44
45 on cardiovascular risk factors: a randomized trial. *Ann Intern Med.* 2006;145:1-11.
46
47
- 48 25. Grundy SM, Cleeman JI, Daniels SR; et al. Diagnosis and management of the metabolic
49
50 syndrome: an American Heart Association/National Heart, Lung, and Blood Institute
51
52 Scientific Statement. *Circulation.* 2005;112:2735-2752.
53
54
55
56
57
58
59
60

- 1
2
3 26. Fernández-Ballart JD, Piñol JL, Zazpe I, et al. Relative validity of a semi-quantitative
4 food-frequency questionnaire in an elderly Mediterranean population of Spain. *Br J Nutr.*
5 2010;103:1808-16.
6
7
8
9
10 27. Mataix J. *Tablas de composición de alimentos (Spanish food composition tables)*, 4th edn.
11 Universidad de Granada, Granada (in Spanish). 2003.
12
13
14 28. Itan Y, Powell A, Beaumont MA, Burger J, Thomas MG. The origins of lactase persistence
15 in Europe. *PLoS Comput Biol.* 2009;5(8):e1000491.
16
17
18
19 29. Agueda L, Urreiziti R, Bustamante M, et al. Analysis of three functional polymorphisms in
20 relation to osteoporosis phenotypes: replication in a Spanish cohort. *Calcif Tissue Int.*
21 2010;87:14-24.
22
23
24
25
26 30. Almon R, Alvarez-Leon EE, Engfeldt P, Serra-Majem L, Magnuson A, Nilsson TK.
27 Associations between lactase persistence and the metabolic syndrome in a cross-sectional
28 study in the Canary Islands. *Eur J Nutr.* 2010; 49:141-6.
29
30
31
32 31. Sacerdote C, Guarrera S, Smith GD, et al. Lactase persistence and bitter taste response:
33 instrumental variables and mendelian randomization in epidemiologic studies of dietary
34 factors and cancer risk. *Am J Epidemiol.* 2007;166:576-81.
35
36
37
38 32. Almon R, Patterson E, Nilsson TK, Engfeldt P, Sjöström M. Body fat and dairy product
39 intake in lactase persistent and non-persistent children and adolescents. *Food Nutr Res.*
40 2010;54.
41
42
43
44 33. Vesa TH, Seppo LM, Marteau PR, Sahi T, Korpela R. Role of irritable bowel syndrome in
45 subjective lactose intolerance. *Am J Clin Nutr* 1998; 67, 710–715.
46
47
48
49 34. Wilt TJ, Shaukat A, Shamliyan T, et al. Lactose intolerance and health. *Evid Rep Technol*
50 Assess 2010;192:1-410.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 35. Hertzler SR, Huynh BC, Savaiano DA. How much lactose is low lactose? *J Am Diet*
4
5 Assoc. 1996;96:243-6.
6
7
8 36. Zhong Y, Priebe MG, Vonk RJ, et al. The role of colonic microbiota in lactose
9
10 intolerance. *Dig Dis Sci.* 2004;49:78-83.
11
12
13 37. Szilagy A, Shrier I, Heilpern D, et al. Differential impact of lactose/lactase phenotype on
14
15 colonic microflora. *Can J Gastroenterol.* 2010;24:373-9.
16
17
18 38. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-
19
20 associated gut microbiome with increased capacity for energy harvest. *Nature.*
21
22 2006;444:1027-31.
23
24
25 39. Armougom F, Henry M, Vialettes B, Raccach D, Raoult D. Monitoring bacterial community
26
27 of human gut microbiota reveals an increase in *Lactobacillus* in obese patients and
28
29 *Methanogens* in anorexic patients. *PLoS One.* 2009;4(9):e7125.
30
31
32 40. Sanz Y, Santacruz A, Gauffin P. Gut microbiota in obesity and metabolic disorders. *Proc*
33
34 *Nutr Soc.* 2010;69:434-41.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Demographic, anthropometric, dietary and genetics characteristics of the studied subjects

	Men (n=338)		Women (n=602)	
	Mean	(SD)	Mean	(SD)
Age (years)*	66	(7)	67	(6)
Weight (Kg)*	81.2	(12.0)	73.4	(11.0)
Height (m)*	1.66	(0.06)	1.55	(0.06)
Waist circumference (cm)*	104	(12)	102	(12)
BMI (Kg/m ²)*	29.5	(3.8)	30.7	(4.4)
Physical activity (kcal/d)*	220	(217)	136	(126)
Total energy intake (kcal/d)*	2384	(669)	2117	(614)
Total fat intake (% energy)	38.7	(7.6)	39.1	(6.9)
Carbohydrates (% energy)	41.8	(7.9)	42.6	(6.9)
Proteins (% energy)*	16.3	(2.7)	17.4	(2.7)
Alcohol (g/d)*	11.7	(14.9)	2.6	(4.8)
Total dairy products (g/d)*	322.3	(193.9)	395.2	(229.6)
Whole-fat milk (g/d)*	43.1	(123.1)	35.3	(120.3)
Partially skimmed milk (g/d)	103.5	(153.1)	127.4	(188.7)
Skimmed milk (g/d)*	77.3	(145.0)	114.8	(191.0)
Whole-fat yoghurt (g/d)	21.9	(54.2)	21.0	(55.5)
Skimmed yoghurt (g/d)*	36.9	(64.4)	56.0	(79.9)
Total cheese (g/d)	30.8	(23.2)	34.3	(27.5)
Lactose (g/d)*	12.9	(8.8)	15.9	(10.4)
Nonconsumers of milk (%)	14.2		14.0	
Current smokers (%)*	27.8		4.1	
Obesity (%)*	42.4		53.5	
Diabetes (%)*	54.4		41.9	
Metabolic syndrome (%)*	53.5		66.8	
LCT (-13910C>T) genotype (%)				
CC (LNP)	39.3		37.2	
CT (LP)	43.5		47.0	
TT (LP)	17.2		15.8	

SD: Standard deviation

The metabolic syndrome was defined according to updated ATP III criteria

*: Statistically significant differences between men and women (Student's t test for continuous variables with normal distribution or the non-parametric Mann-Whitney U test for dairy products, alcohol and physical activity. Chi square tests for categorical variables)

LNP: Lactase non-persistence; LP: Lactase persistence

Table 2: Association of the LCT rs4988235 polymorphism with dairy product consumption in the elderly Mediterranean population

	Whole population			Men			Women		
	CC	CT+TT	P	CC	CT+TT	P	CC	CT+TT	P
	LNP (n=357)	LP (n=583)		LNP (n=133)	LP (n=205)		LNP (n=283)	LP (n=378)	
	Mean (SD)	Mean (SD)		Mean (SD)	Mean (SD)		Mean (SD)	Mean (SD)	
Age (years)	67.5 (6.1)	66.8 (6.1)	0.075	66.9 (6.4)	66.2 (7.0)	0.472	67.8 (6.0)	67.1 (5.5)	0.153
Total energy intake (kcal/d)	2228.2 (646.3)	2204.4 (648.1)	0.599	2404.6 (683.9)	2370.8 (661.3)	0.617	2121.9 (599.7)	2113.9 (623.4)	0.882
Total dairy products (g/d)	354.1 (198.6)	377.8 (231.8)	0.124	330.2 (187.0)	317.1 (198.5)	0.387	368.5 (204.3)	410.7 (242.0)	0.045
Whole-fat milk (g/d)	46.1 (134.7)	33.2 (112.3)	0.068	45.4 (113.7)	41.6 (129.0)	0.440	46.6 (146.1)	28.6 (101.9)	0.088
Partially skimmed milk (g/d)	112.2 (165.4)	122.8 (183.6)	0.642	107.8 (160.0)	100.7 (148.8)	0.855	114.8 (168.9)	134.8 (199.2)	0.491
Skimmed milk (g/d)	96.9 (166.0)	103.9 (182.9)	0.942	84.0 (146.7)	73.0 (144.1)	0.292	104.7 (176.5)	120.8 (199.0)	0.434
Condensed milk (g/d)	0.2 (2.2)	0.2 (2.0)	0.311	0.1 (1.1)	0.1 (0.8)	0.589	0.2 (2.7)	0.3 (2.5)	0.639
Total milk (g/d)	255.4 (181.9)	260.2 (199.0)	0.856	237.3 (162.0)	215.4 (174.4)	0.125	266.3 (192.5)	284.5 (207.4)	0.468
Whole-fat yoghurt (g/d)	21.2 (52.4)	21.4 (56.5)	0.541	26.8 (60.3)	18.7 (49.7)	0.204	17.8 (46.8)	22.8 (60.0)	0.818
Skimmed yoghurt (g/d)	39.4 (60.9)	55.0 (82.1)	0.004	29.2 (54.6)	41.9 (69.7)	0.150	45.6 (63.7)	62.1 (87.4)	0.016
Skimmed milk and yoghurt (g/d)	248.5 (200.6)	317.6 (239.2)	0.053	221.0 (185.6)	215.6 (184.9)	0.762	265.1 (207.9)	317.6 (239.2)	0.014
Whipped cream (g/d)	0.2 (1.2)	0.4 (4.6)	0.305	0.2 (1.0)	0.8 (7.4)	0.699	0.2 (1.3)	0.3 (1.5)	0.321
Milkshake (g/d)	0.9 (10.0)	1.4 (15.3)	0.478	1.3 (14.1)	0.8 (6.7)	0.259	0.6 (6.3)	1.8 (18.4)	0.975
Ricotta cheese or junket (g/d)	1.5 (8.4)	1.4 (8.0)	0.378	1.4 (6.7)	1.4 (8.6)	0.991	1.6 (9.2)	1.4 (7.6)	0.268
Petit Suisse cheese (g/d)	0.6 (4.8)	0.3 (3.0)	0.717	0.0 (0.0)	0.0 (0.0)	0.980	0.9 (6.1)	0.4 (3.5)	0.927
Spreadable cheese wedges (g/d)	0.9 (2.7)	1.4 (4.8)	0.646	1.1 (3.1)	1.2 (4.1)	0.602	0.8 (2.5)	1.5 (5.1)	0.323
Cottage cheese (g/d)	13.0 (14.4)	15.7 (20.2)	0.101	9.5 (11.1)	12.6 (17.9)	0.296	15.1 (15.7)	17.4 (21.2)	0.274
Other cheese (hard cheese) (g/d)	16.1 (18.1)	14.8 (14.5)	0.739	18.0 (18.2)	16.0 (13.6)	0.706	15.0 (18.0)	14.1 (14.9)	0.914
Custard (g/d)	3.1 (11.9)	2.5 (8.8)	0.615	3.7 (13.4)	3.5 (11.5)	0.324	2.8 (10.9)	2.0 (6.9)	0.805
Ice cream (g/d)	1.8 (4.7)	3.2 (14.8)	0.873	1.9 (3.7)	4.5 (21.2)	0.966	1.8 (5.3)	2.4 (9.7)	0.755
Lactose (g/d)	14.4 (9.2)	15.1 (10.4)	0.441	13.4 (8.3)	12.6 (9.1)	0.311	15.0 (9.6)	16.5 (10.9)	0.115

SD: Standard deviation

P values for the comparison of means between CC and CT+TT subjects for dairy products were carried out by the non-parametric Mann-Whitney U test

Table 3: Association of the LCT rs4988235 polymorphism with anthropometric variables in the elderly Mediterranean population

	CC		CT+TT				
	LNP (n=357)		LP (n=583)				
	Mean	(SD)	Mean	(SD)	P1	P2	P3
Age (years)	67.5	(6.1)	66.8	(6.1)	0.080		
Height (m)	1.59	(0.08)	1.59	(0.08)	0.392	0.314	0.333
Weight (Kg)	75.2	(12.3)	76.8	(11.7)	0.044	0.032	0.021
BMI (Kg/m ²)	29.7	(4.2)	30.6	(4.2)	0.003	0.004	0.002
Waist circumference (cm)	101.1	(11.8)	103.5	(11.5)	0.005	0.002	0.002
Obesity prevalence (%)	45.4		53.7		0.014		
OR for obesity and (95% CI)	1	(reference)	1.39	(1.07-1.82)	0.014		
			1.39	(1.06-1.81)		0.017	
			1.37	(1.03-1.81)			0.029

SD: Standard deviation

P1: Unadjusted P value

P2: Model adjusted for sex and age

P3: Model adjusted for sex, age, diabetes, total energy intake and physical activity

Table 4: Association of the LCT rs4988235 polymorphism with plasma lipids, glucose, and blood pressure. Adjusted means*

	CC		CT+TT		P
	LNP (n=357)		LP (n=583)		
	Mean	(SE)	Mean	(SE)	
Total cholesterol (mg/dL)	206.6	(2.2)	204.4	(1.8)	0.418
LDL-C (mg/dL)	129.67	(2.09)	127.10	(1.64)	0.324
HDL-C (mg/dL)	51.3	(0.7)	52.1	(0.6)	0.349
Triglycerides (mg/dL)	136.7	(4.6)	129.3	(3.6)	0.198
Fasting glucose (mg/dL)**	121.3	(1.8)	121.7	(1.4)	0.868
Systolic blood pressure (mm Hg)	146.3	(1.2)	147.4	(0.9)	0.422
Diastolic blood pressure (mm Hg)	81.7	(0.7)	82.6	(0.5)	0.309

SE: Standard error

**Means were adjusted for sex, age and BMI*

*** : Means were additionally adjusted for diabetes*

LEGENDS TO FIGURES

Figure 1: Modulation by dairy lactose intake of the association between the *LCT* -13910C>T polymorphism and waist circumference (cm) in the elderly Mediterranean population: Panel **A**, predicted values of waist circumference by the *LCT* -13910C>T (n=357 CC individuals and n=576 T-allele carriers (8 outliers with lactose intake higher than 50 g/d were removed to improve normality for the statistical analysis) depending on the lactose consumed (as continuous) are depicted. Predicted values were calculated from the regression models containing lactose intake, the *LCT* polymorphism, their interaction term, and the potential confounders [sex, age (as continuous), diabetes (as categorical), total energy intake (as continuous) and physical activity (as continuous)]. Predicted values for this model were obtained for each individual. The P value for the interaction term was obtained in the multivariate interaction model. Panel **B** represents adjusted means of waist circumference (cm) in the study subjects (n=940) depending on the *LCT* -13910C>T polymorphism according to 3 strata of lactose intake: low [≤ 8 g lactose/d; 20% of the population (n=68 CC, 122 CT+TT)], intermediate [8-24 g lactose/d; 50% of the population (n=188 CC, 284 CT+TT)], and high [> 24 g lactose/d; 30% of the population (n=101 CC, 177 CT+TT)]. Estimated means were adjusted for sex, age (as continuous), diabetes (as categorical), total energy intake (as continuous) and physical activity (as continuous). P values for genotype comparisons in each strata were estimated after multivariate adjustment for the covariates indicated above. Bars indicate standard error (SE) of means.

Fig 1

